NL-OMON33240
已完成
不适用
An Open-Label Drug-Drug Interaction Study in Healthy Male Subjects to Explore the Effects of Single and Multiple Doses of JNJ-39393406 on the Pharmacokinetics of a Single Oral Dose of Midazolam - JNJ-39393406 ALZ1001 study
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- alzheimer
- 发起方
- Janssen-Cilag
- 入组人数
- 12
- 状态
- 已完成
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Between 18 and 55 years of age (inclusive)
- •BMI between 18 en 30 kg/m^2 (inclusive)
排除标准
- •Clinical significant abnormalities for physical examination
结局指标
主要结局
未指定
相似试验
已完成
不适用
An Open-Label Two-Way Drug-Drug Interaction Study to Assess the Effect of Tenofovir on the Pharmacokinetics of BMS-790052 and the Effect of BMS-790052 on the Pharmacokinetics of Tenofovir in Healthy SubjectsHepatitis Cviral liver inflammation10047438NL-OMON36725Bristol-Myers Squibb21
进行中（未招募）
1 期
An Open-label Drug-Drug Interaction Study to Assess the Effects ofNemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Serve Atopic DermatitisModerate-to-severe atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2020-000229-24-BGGalderma S.A.25
未知
1 期
Phase 1 Drug-Drug Interaction Study between TAK-272 and Itraconazole, Digoxin and MidazolamJPRN-jRCT2080222758TAKEDA PHARMACEUTICAL COMPANY LTD.34
未知
3 期
An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult maleHealthy adult maleJPRN-jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12
进行中（未招募）
1 期
A study in healthy volunteers to discover how the test medicine interacts with other approved medicines1. Non-alcoholic steatohepatitis (NASH)2. Antipsychotic-induced weight gain (AIWG)Not ApplicableISRCTN10379288Corcept Therapeutics (United States)30